HER2阴性晚期胃癌患者PD-1抑制剂信迪利单抗治疗过程中癌胚抗原变化及其与预后的关系  

Changes in carcinoembryonic antigen during the treatment of HER 2 negative advanced gastric cancer patients with PD-1 inhibitor Sintilimab and its relationship with prognosis

作　　者：宋永波[1] 杜小明[1] 张艳苓[1] 赵璐[1] SONG Yongbo;DU Xiaoming;ZHANG Yanling;ZHAO Lu(Department of Oncology,North Anhui Coal Power Group General Hospital,Suzhou 234000,China)

机构地区：[1]皖北煤电集团总医院肿瘤内科,宿州234000

出　　处：《中国免疫学杂志》2025年第2期402-407,共6页Chinese Journal of Immunology

摘　　要：目的:探究人类表皮生长因子受体2(HER2)阴性晚期胃癌患者程序性死亡蛋白1(PD-1)抑制剂信迪利单抗免疫过程中癌胚抗原(CEA)变化及其与预后的关系。方法:选择2020年5月至2022年4月于皖北煤电集团总医院治疗的HER2阴性晚期胃癌患者(88例)为研究对象,均行PD-1抑制剂信迪利单抗治疗;根据预后情况分为死亡组(36例)和生存组(52例)。每6个月随访1次,收集患者治疗前后肿瘤标志物水平。分析肿瘤标志物(CEA、CA199、CA125)水平与临床分期、淋巴结转移及预后的关系。采用Kaplan-Meier生存曲线分析各肿瘤标志物阴性及阳性组患者的生存时间。采用多因素Cox回归模型和逐步回归分析影响预后的危险因素。采用Spearman进行相关性分析。结果:治疗2个周期后,疾病控制者72例(81.82%)、进展者16例(18.18%)。与治疗前相比,治疗后患者血清肿瘤标志物阳性率均显著降低(P<0.05)。CEA、CA199阳性率与临床分期显著相关(P<0.05)。预测患者死亡时,CEA水平的敏感度最高(48.57%),而CA125的特异度最高(95.62%),但敏感度最低(25.71%)。Kaplan-Meier生存曲线分析结果显示,各肿瘤标志物阳性患者的生存时间均显著短于阴性患者(P<0.05)。临床分期、血清CEA和CA199水平均为预测预后的独立因素(P<0.05)。Spearman相关性分析结果显示,CEA(r=-0.512,P=0.005)、CA199(r=-0.467,P=0.011)升高倍数与患者的生存时间均呈负相关。结论:经PD-1抑制剂信迪利单抗治疗后,HER2阴性晚期胃癌患者的血清肿瘤标志物水平均显著降低。患者血清高CEA、CA199、CA125水平均可预测不良预后,临床分期、血清CEA和CA199水平均为预测预后的独立因素。CEA、CA199升高倍数越高,患者生存时间越短。Objective:To explore the changes in carcinoembryonic antigen(CEA)during the immune process of programmed death-1(PD-1)inhibitor Sintilimab in human epithelial growth factor receptor 2(HER2)negative advanced gastric cancer patients and its relationship with prognosis.Methods:HER2 negative late stage gastric cancer patients(88 cases)who were treated in North Anhui Coal Power Group General Hospital from May 2020 to April 2022 were selected as study subjects,all of whom received PD-1 inhibitor Sintilimab treatment;according to the prognosis,they were divided into death group(36 cases)and survival group(52 cases).Followed up was conducted every 6 months to collect tumor marker levels before and after treatment.Analyzed relationship between tumor markers(CEA,CA199,CA125)levels and clinical staging,lymph node metastasis and prognosis.Kaplan-Meier sur‐vival curve was used to analyze survival time of patients with negative and positive tumor markers.Multivariate Cox regression model and stepwise regression analysis were used to identify risk factors affecting prognosis.Spearman was used for correlation analysis.Results:After two cycles of treatment,72 cases(81.82%)had disease control and 16 cases(18.18%)had progression.Compared with patients before treatment,positive rate of serum tumor markers in patients after treatment was significantly reduced(P<0.05).Positive rates of CEA and CA199 were significantly correlated with clinical staging(P<0.05).When predicting patient death,sensitivity of CEA level was the highest(48.57%),while CA125 had the highest specificity(95.62%)and the lowest sensitivity(25.71%).Kaplan-Meier survival curve analysis showed that the survival time of patients with positive tumor markers were significantly shorter than that of negative patients(P<0.05).Clinical staging,serum CEA and CA199 levels were independent factors for predicting prognosis(P<0.05).Spearman correlation analysis results showed that the multiple increases in CEA(r=-0.512,P=0.005)and CA199(r=-0.467,P=0.011)were negatively correlate

关 键 词：HER2阴性 胃癌 信迪利单抗 癌胚抗原 预后 

分 类 号：R730.7[医药卫生—肿瘤]